COCHLEAR LTD-UNSPON ADR Business Summary

Cochlear Ltd (CHEOY) is the global leader in implantable hearing solutions, generating revenue primarily through the design, manufacture, and distribution of three core segments: Cochlear Implants (Nucleus), Services (upgrades and accessories), and Acoustics (Baha and Osia bone conduction systems). The company utilizes a direct-to-clinical and hospital-based sales model, supplemented by a recurring revenue stream from its "Services" division, which caters to an expanding global installed base of over 750,000 recipients. As of mid-2026, the firm has pivoted toward a platform-based care model with the launch of the Nucleus Nexa System, emphasizing firmware-upgradeable hardware and AI-driven sound processing. Cochlear maintains a dominant market share of approximately 60%, competing directly with Sonova (Advanced Bionics), MED-EL, and Demant (Oticon Medical). It distinguishes itself through the industry's largest R&D investment and a strategic focus on "medicalizing" hearing loss to penetrate the underserved adult and senior demographics. Founded by Professor Graeme Clark, who pioneered the multi-channel cochlear implant, the company is currently led by CEO and President Dig Howitt, a former Boston Consulting Group (BCG) consultant who has been with the firm since 2000. The executive bench was recently strengthened by the appointment of CFO Dr. Sarah Thom in January 2025, a former Managing Director at BCG with a PhD in Astrophysics, and CTO Jan Janssen, who oversees a global team of over 600 scientists and holds numerous patents in implantable technology. The Board is chaired by Alison Deans, a veteran executive with prior leadership roles at eBay and Hoyts Cinemas. Notable institutional backing includes significant positions held by BlackRock, State Street Global Advisors, and AustralianSuper, reflecting the company’s status as a core healthcare holding with a robust long-term innovation pipeline.